Emory University;President and Fellows of Harvard College;Dana-Farber Cancer Institute, Inc.
发明人:
申请号：
EP16160525.8
公开号：
EP3064220A3
申请日:
2007.12.26
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In additions, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
